OR WAIT 15 SECS
The partners will explore Dyadic’s C1 gene expression platform in conjunction with IIBR’s express gene sequences and targets to develop a potential vaccine candidate and monoclonal antibodies.
Dyadic International, a biotechnology company located in Jupiter, FL, announced on Feb. 25, 2020 that it is partnering with The Israel Institute for Biological Research (IIBR) to join the fight against the novel coronavirus (COVID-19) by exploring Dyadic’s C1 gene expression platform in conjunction with IIBR’s express gene sequences and targets.
According to a Dyadic press release, the collaboration will use Dyadic’s platform and IIBR’s express gene sequences and targets to develop a potential vaccine candidate and monoclonal antibodies to help fight the current COVID-19 outbreak.
"Our collaboration with the IIBR is aimed at finding additional solutions to combat the COVID-19 coronavirus outbreak that threatens the lives of people in China and globally," said Mark A. Emalfarb, founder and CEO of Dyadic, in the press release. "There is a global need to apply new platforms and technologies that will facilitate a fast, coordinated, and practical response to new infectious diseases during pandemic and epidemic outbreaks or a bioterrorist attack, and we believe that Dyadic's C1 technology is well-positioned to contribute to this global effort."
"The Israel Institute for Biologcal Research was assigned by the Israeli Prime minister, Mr. Benjamin Netanyahu, to act as quickly as possible to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19," added Professor Shmuel C. Shapira, director general of IIBR, in the press release. "More than 50 experienced PhD IIBR's scientists are working tirelessly to produce a vaccine and neutralizing antibodies for the novel coronavirus COVID-19. This is a world-leading group in aspect of knowledge, experience, and infrastructure. The Israel Institute for Biological Research was assigned to the task based on its proven professional scientific capabilities and previous successes in the field."
Related Content:COVID-19 Update